3-(4-{2-[2-(trifluoromethyl)-1H-benzo[d]imidazol-4-yloxy]ethyl}piperazin-1-yl)benzene-1,2-diamine | 888016-53-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-(4-{2-[2-(trifluoromethyl)-1H-benzo[d]imidazol-4-yloxy]ethyl}piperazin-1-yl)benzene-1,2-diamine
• 英文别名: 3-{4-[2-(2-Trifluoromethyl-1H-benzoimidazol-4-yloxy)-ethyl]piperazin-1-yl}-benzene-1,2-diamine；3-{4-[2-(2-Trifluoromethyl-1H-benzoimidazol-4-yloxy)-ethyl]-piperazin-1-yl}-benzene-1,2-diamine；3-[4-[2-[[2-(trifluoromethyl)-1H-benzimidazol-4-yl]oxy]ethyl]piperazin-1-yl]benzene-1,2-diamine
• CAS: 888016-53-3
• 化学式: C₂₀H₂₃F₃N₆O
• 分子量: 420.437
• InChiKey: WCORUMIRJVPQPN-UHFFFAOYSA-N

物化性质

• 沸点：
  635.3±55.0 °C(Predicted)
• 密度：
  1.390±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  96.4
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  3-(4-{2-[2-(trifluoromethyl)-1H-benzo[d]imidazol-4-yloxy]ethyl}piperazin-1-yl)benzene-1,2-diamine 、 4-异丙基苯甲酸 在 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 溶剂黄146 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 2.0h， 生成 2-(4-isopropylphenyl)-4-(4-{2-[2-(trifluoromethyl)-1H-benzo[d]imidazol-4-yloxy]ethyl}piperazin-1-yl)-1H-benzo[d]imidazole
  参考文献：
  名称：

  2-Phenyl-4-piperazinylbenzimidazoles: Orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor

  摘要：

  Antagonism of the gonadotropin releasing hormone (GnRH) receptor has shown positive clinical results in numerous reproductive tissue disorders such as endometriosis, prostate cancer and others. Traditional therapy has been limited to peptide agonists and antagonists. Recently, small molecule GnRH antagonists have emerged as potentially new treatments. This article describes the discovery of 2-phenyl-4-piperazinylbenzimidazoles as small molecule GnRH antagonists with nanomolar potency in in vitro binding and functional assays, excellent bioavailability (rat % F > 70) and demonstrated oral activity in a rat model having shown significant serum leuteinizing hormone (LH) suppression. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.05.024
• 作为产物：
  描述：

  4-{2-[4-(3-azido-2-nitrophenyl)piperazin-1-yl]ethoxy}-2-(trifluoromethyl)-1H-benzo[d]imidazole 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 以100%的产率得到3-(4-{2-[2-(trifluoromethyl)-1H-benzo[d]imidazol-4-yloxy]ethyl}piperazin-1-yl)benzene-1,2-diamine
  参考文献：
  名称：

  Gonadotropin releasing hormone receptor antagonists

  摘要：

  这项发明涉及促性腺激素释放激素（“GnRH”）（也称为黄体生成素释放激素）受体拮抗剂。

  公开号：

  US20060111355A1

文献信息

• Gonadotropin releasing hormone receptor antagonists
  申请人：Garrick Michael Lloyd

  公开号：US20060111355A1

  公开（公告）日：2006-05-25

  The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

  这项发明涉及促性腺激素释放激素（“GnRH”）（也称为黄体生成素释放激素）受体拮抗剂。
• GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS
  申请人：Wyeth

  公开号：EP1814866A2

  公开（公告）日：2007-08-08
• [EN] GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR D'HORMONE DE LIBERATION DE GONADOTROPINE
  申请人：WYETH CORP

  公开号：WO2006058012A2

  公开（公告）日：2006-06-01

  [EN] The present invention relates to Gonadotropin Releasing Hormone ("GnRH") (also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.
  [FR] L'invention porte sur des antagonistes du récepteur d'hormone de libération de gonadotropine ("GnRH") (également dénommée hormone de libération de l'hormone lutéinisante).
• 2-Phenyl-4-piperazinylbenzimidazoles: Orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor
  作者：Jeffrey C. Pelletier、Murty Chengalvala、Josh Cottom、Irene Feingold、Lloyd Garrick、Daniel Green、Diane Hauze、Christine Huselton、James Jetter、Wenling Kao

  DOI：10.1016/j.bmc.2008.05.024

  日期：2008.7.1

  Antagonism of the gonadotropin releasing hormone (GnRH) receptor has shown positive clinical results in numerous reproductive tissue disorders such as endometriosis, prostate cancer and others. Traditional therapy has been limited to peptide agonists and antagonists. Recently, small molecule GnRH antagonists have emerged as potentially new treatments. This article describes the discovery of 2-phenyl-4-piperazinylbenzimidazoles as small molecule GnRH antagonists with nanomolar potency in in vitro binding and functional assays, excellent bioavailability (rat % F > 70) and demonstrated oral activity in a rat model having shown significant serum leuteinizing hormone (LH) suppression. (c) 2008 Elsevier Ltd. All rights reserved.